Difference between pages "Deodorants Market Analysis: Acquisition of Sanex by Colgate" and "Boston Scientific - Company Profile"

From DolceraWiki
(Difference between pages)
Jump to: navigation, search
 
(→‎Key Insights)
 
Line 1: Line 1:
−
==Introduction==
+
==Boston Scientific==
 +
===Company Overview===
 +
====Key Facts====
 +
Boston Scientific (founded in 1979) is a worldwide developer, manufacturer and marketer of medical devices with approximately 25,000 employees and revenue of $7.8 billion in 2010. For more than 30 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The company<nowiki>’</nowiki>s products help physicians and other medical professionals improve their patients<nowiki>’</nowiki> quality of life by providing alternatives to surgery.
  
−
<u>'''Acquisition of Sanex by Colgate'''</u>
+
{|border="2" cellspacing="0" cellpadding="1" width="50%" align="center"
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Type'''</font>
 +
|<font color="#333333">Public Company</font>
 +
|-
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Company Size'''</font>
 +
|<font color="#333333">10,001<nowiki>+</nowiki> employees</font>
 +
|-
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Website'''</font>
 +
|<font color="#0000FF"><u>[http://www.linkedin.com/redirect?url=http%3A%2F%2Fwww%2Ebostonscientific%2Ecom&urlhash=a7R8 http://www.bostonscientific.com]</u></font>
 +
|-
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Industry'''</font>
 +
|<font color="#333333">Medical Devices</font>
 +
|-
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Founded'''</font>
 +
|<font color="#333333">1979</font>
 +
|-
 +
|}
  
−
* Colgate-Palmolive Co. (CL) has acquired Unilever<nowiki>’</nowiki>s Sanex personal-care unit for about $940 million, to expand in deodorant and body wash overseas.
+
=====Primary business divisions=====
−
* Colgate has also sold its Colombian laundry detergent business to Unilever for $215 million.
+
# Cardiology, Rhythm and Vascular
−
* Sanex, which Unilever had to sell to fulfill the [[Legal obligations of EU Antitrust Laws]], generated sales of about $260 million in 2009.
+
# Endoscopy
−
* The acquisition is Colgate<nowiki>’</nowiki>s first since 2006 as Chief Executive Officer Ian Cook aims to expand into more profitable products.
+
# Urology and Women<nowiki>’</nowiki>s Health
−
* Colgate, which generates more than 80 percent of sales outside North America, will gain a foothold in key parts of the personal-care market in Western Europe as a result of the transaction
+
# Neuromodulation
−
<br/>
+
  
−
<u>'''Asset Disposal by Unilever'''</u>
+
=====Key products=====
  
−
* Unilever, which bought Sanex as part of its 1.2 billion euro ($1.7 billion) acquisition of Sara Lee Corp. (SLE)<nowiki>’</nowiki>s international toiletries unit, was forced to dispose of the brand by the European Union, which raised concerns about competition issues in Europe.
+
1) Taxus, Liberté, and Express coronary stents
−
* Combining Sanex with the company<nowiki>’</nowiki>s Dove and Rexona brands would "likely have led to price increases" in seven countries including the U.K. and Spain, according to the European Commission.
+
−
* Sanex also drew interest from Procter & Gamble Co and Henkel AG, people briefed on the discussions said this month. Unilever didn<nowiki>’</nowiki>t want to sell the business, because Sanex was the brand it wanted most, according to the people.
+
−
* Colgate will pay all cash for the shares and net assets and expects to close the acquisition by the end of the second quarter.
+
−
* Colgate is planning to expand its portfolio of brands that can help Colgate increase its competitive strength.
+
  
−
<br/>
+
2) Cognis cardiac resynchronization therapy defibrillator
  
−
Colgate needs research support in taking the decision.
+
3) Confient, Teligen, and Vitality implantable cardioverter defibrillators
  
−
==Market overview==
+
4) Explorer and Inquiry diagnostic cardiology catheters
−
<br/>
+
−
<u>'''Introduction to the market'''</u>
+
  
−
* The world market for deodorants registered growth during the years 2008 and 2009, albeit at a slower rate than in previous years.
+
5) iLab ultrasound imaging system; Atlantis SR Pro ultrasound imaging catheter
−
* With the recovery from the financial crisis in 2010, the market is projected to post healthy growth in the coming years driven by manufacturers increased focus on delivering technologically advanced products in various novel product formats.
+
−
* In addition, rising demand for gender-specific products is expected to enhance market prospects.
+
−
* Further, growing population, increasing awareness and rise in disposable incomes among consumers in developing regions including Asia-Pacific and Latin America would contribute to enhanced deodorant sales.
+
−
* Deodorants is a matured market in developed regions such as the US and Europe. In these markets, delivery of innovative products and an '''improved product mix''' play a vital role for manufacturers to increase their revenues.
+
−
* Producers are more or less compelled to offer innovative products that deliver quick, effective protection against odor and wetness.
+
−
* Deodorant producers have sought to generate sales growth by relying on product introductions on a continuous basis as well as '''product line extensions.'''
+
−
<br/>
+
  
−
<u>'''Europe Market'''</u>
+
6) Polyflex, Ultraflex and Wallflex esophageal, duodenal, and colonic stents
  
−
* Europe represents the largest regional market for deodorants worldwide.
+
7) Sterling balloon dilation catheters
−
* Europe along with the US collectively account for a major share of the global deodorants sales.
+
−
* Demand for deodorants in Europe as well as the US reported a moderate drop during 2009 because of economic slowdown that forced consumers to cut down spending on certain avoidable products such as deodorants.
+
−
* Deodorant Market can be further segmented into aerosol sprays, non-aerosol sprays, and squeeze-bottle sprays. Aerosol Sprays constitute the largest as well as fastest growing product segment of deodorants in the world.
+
−
* Stick & Solid Deodorants category represents the second major deodorants product segment.
+
−
* The personal care category is witnessing a strong growth trend as a result of the increasing focus of men towards grooming, hygiene and appearance. Male oriented products are growing briskly, surpassing the hitherto women dominated cosmetics and personal care market.
+
−
* With regard to fragrances, '''men choose deodorants over the luxurious perfumes''' which are preferred by females. This has provided a definite impetus to the overall sales of deodorants.
+
−
* Another major trend in the deodorants market includes the shift towards more '''natural products'''. The increase in awareness about the benefits of natural products, led to a rise in demand for deodorants using herbs and botanicals. Botanical ingredients such as cucumber, aloe vera, lemongrass, and green tea are increasingly being used in deodorants to lure health-conscious individuals.
+
  
−
<br/>
+
8) VersaPulse PowerSuite holmium urology laser systems
  
 +
([http://www.pharmalive.com/special_reports/sample.cfm?reportID=309 Pharmalive])
  
−
===Market Size===
+
=====Significant subsidiaries=====  
−
<br/>
+
  
−
====Total Market Size====
+
1) Advanced Stent Technologies Inc.
−
[[image:2_3_1.JPG|thumb|705×406px|center|European Market Size|Source: Euromonitor]]
+
−
<u>'''Key Insights'''</u>
+
  
−
- Western Europe market is saturated with a value as high as 5000 m USD
+
2) Boston Scientific Neuromodulation Corp.
  
−
- Eastern Europe market has lots of scope and is expected to grow, as more countries move towards Free Market Economy
+
3) Cardiac Pacemakers Inc.
  
 +
4) Catheter Innovations Inc.
  
−
<br/>
+
5) Corvita Corp.
  
−
====Product wise Market Size====
+
6) EndoVascular Technologies Inc.
−
<br/>
+
  
−
=====Western Europe=====
+
7) Enteric Medical Technologies Inc.
−
[[image:2_3_1_9.JPG|thumb|709×495px|center|European Market Size|Source: Euromonitor]]
+
−
<br/>
+
  
−
=====Eastern Europe=====
+
8) Guidant Corp.
−
[[image:2_3_1_8.JPG|thumb|709×495px|center|European Market Size|Source: Euromonitor]]
+
−
<br/>
+
  
−
<u>'''Key Insights'''</u>
+
9) Intermedics Inc.
  
−
- Deodorants roll on and sprays are preferred more in western Europe while in Eastern Europe stick ons are expected to have a have a huge market
+
10) Interventional Technologies LLC
  
−
- Product Offerings for Colgate in Eastern and Western Europe should contain spray format and should have stick ons and roll ons in their offerings in these countries, respectively
+
11) Precision Vascular Systems Inc
  
−
- People in Eastern Europe are more Price Conscious due to communist regimes / mixed economies and hence, share of sticks in Eastern market is more as compared to Western Europe
+
([http://www.pharmalive.com/special_reports/sample.cfm?reportID=309 Pharmalive])
  
−
<br/>
+
====Key Financials====
  
−
===Market Share===
+
{|border="2" cellspacing="0" cellpadding="4" width="49%"
−
<br/>
+
|align = "center" bgcolor = "#002060" colspan = "2"|<font color="#FFFFFF">'''Financials of Boston Scientific in 2010 (in $M)'''</font>
−
 
+
−
====Western Europe====
+
−
<br/>
+
−
<u>'''Market Share of Various Companies between 2005-10 in Western Europe'''</u> <br/>
+
−
<br>
+
−
 
+
−
[[Image:2_3_1_7.JPG|thumb|710×495px|center|European Market Size|Source: Euromonitor]]
+
−
<br/>
+
−
[[Market Share of Various Companies in 2010 - Western Europe]]
+
−
<br/>
+
−
 
+
−
====Eastern Europe====
+
−
 
+
−
<br/>
+
−
<u>'''Market Share of Various Companies between 2005-10 in Eastern Europe'''</u> <br/>
+
−
<br>
+
−
 
+
−
[[Image:2_3_1_6.JPG|thumb|708×492px|center|European Market Size|Source: Euromonitor]]
+
−
<br/>
+
−
[[Market Share of Various Companies in 2010 - Eastern Europe]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Key Insights'''</u>
+
−
 
+
−
- Western Europe has two major players – Unilever and Beiersdorf, while the rest of the industry is moving towards consolidation which is a sign of saturated market, '''which can only be revived by continues product innovations'''
+
−
 
+
−
- Eastern Europe has three major players but no market leader, hence the shares are evenly distributed and the industry is fragmented into a lot of small players, while the scope of growth remains high
+
−
 
+
−
<br/>
+
−
 
+
−
===Country-wise Share===
+
−
<br/>
+
−
====Western Europe====
+
−
<br/>
+
−
<u>'''Sales Value'''</u>
+
−
 
+
−
[[Sales Value Past Trends]]<br/>
+
−
[[Sales Value Future Trends]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Value Growth'''</u>
+
−
 
+
−
[[ Value Growth Past Trends]]<br/>
+
−
[[Value Growth Future Trends]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Per Capita Spending'''</u>
+
−
 
+
−
[[Per Capita Spending Past Trends]]<br/>
+
−
[[Per Capita Spending Future Trends]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Key Insights'''</u>
+
−
 
+
−
- France, Germany, Italy and UK are the biggest markets for Deodorants and are saturated to a good extent.
+
−
 
+
−
- in next five years Spain and Netherlands are expected to grow and thus marketing expenditure by Colgate can be targeted accordingly
+
−
 
+
−
- in Switzerland, France, Germany, Denmark and Belgium are the countries where the '''Premium brand Sanex''' can be targeted as Per capita spend in these countries is very high
+
−
<br/>
+
−
<br/>
+
−
 
+
−
====Eastern Europe====
+
−
<br/>
+
−
<u>'''Sales Value'''</u>
+
−
 
+
−
[[Past Trends in Sales Value]]<br/>
+
−
[[Future Trends in Sales Value]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Value Growth'''</u>
+
−
 
+
−
[[Future Trends in Value Growth]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Per Capita Spending'''</u>
+
−
 
+
−
[[Past Trends in Per Capita Spending]]<br/>
+
−
[[Future Trends in Per Capita Spending]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Key Insights'''</u>
+
−
<br/>
+
−
- Market in Poland and Russia is expected to grow in next five years while market will saturate in other countries
+
−
 
+
−
- Spend per capita is high in countries – Czech, Poland and Slovak republic, while in coming next five years, the per capita spend by Poland is expected to grow, while other countries might become price sensitive to the product
+
−
 
+
−
<br/>
+
−
 
+
−
===Brand wise Share===
+
−
<br/>
+
−
 
+
−
====Western Europe====
+
−
<br/>
+
−
<u>'''Brand-wise share of Deodorants in Western Europe during 2010'''</u> <br/>
+
−
<br>
+
−
 
+
−
[[Image:0_11_0_1.JPG|thumb|707×414px|center|European Market Size|Source: Euromonitor]]
+
−
<br/>
+
−
[[Trends in Brand-wise Share between 2005-10 - Western Europe]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Key Insights'''</u>
+
−
<br/>
+
−
- There is no clear leader in the Western European Deodorant Market, Nivea is the market leader but it is closely followed by other brands
+
−
 
+
−
- In such a scenario, much of the growth will depend upon Marketing and Advertising capabilities of the organizations along with the ability to differentiate offerings
+
−
 
+
−
- Unilever by far has the largest market share due to its ability to differentiate its offerings
+
−
 
+
−
- Sanex which is a Premium Priced Deodorant has a considerable market share of 4% due to high disposable incomes of people in this region
+
−
 
+
−
<br/>
+
−
 
+
−
====Eastern Europe====
+
−
<br/>
+
−
<u>'''Brand-wise share of Deodorants in Eastern Europe during 2010'''</u> <br/>
+
−
<br>
+
−
 
+
−
[[Image:2_3_1_4.JPG|thumb|709×410px|center|European Market Size|Source: Euromonitor]]
+
−
<br/>
+
−
[[Trends in Brand-wise Share between 2005-10 - Eastern Europe]]
+
−
<br/>
+
−
<br/>
+
−
 
+
−
<u>'''Key Insights'''</u>
+
−
<br/>
+
−
- East European Market has tremendous potential for growth
+
−
 
+
−
- Rexona and Nivea have the maximum Market share, having a significant lead of 6% over its nearest rival
+
−
 
+
−
- Sanex is currently not present in East European Market, since the disposable income of these people is quite low. However, sice the trend is changing there is an opportunity for the brand
+
−
 
+
−
==Consumer Behavior==
+
−
<br/>
+
−
 
+
−
===Consumer Behaviour Trends in Europe===
+
−
 
+
−
====Trends in Men and Women====
+
−
[[Image:C_MF_F.JPG|centre|1160×408px]]
+
−
<br/>
+
−
 
+
−
===Geography Wise Consumer Behaviour Trends===
+
−
<br/>
+
−
 
+
−
====Western Europe - United Kingdom and France====
+
−
[[Image:C_UF_F.JPG|centre|1166×394px]]
+
−
<br/>
+
−
 
+
−
====Eastern Europe - Russia====
+
−
[[Image:C_RU.JPG|centre|550×550px]]
+
−
<br/>
+
−
&nbsp;
+
−
 
+
−
==Brand Valuation==
+
−
<br/>
+
−
 
+
−
===Price Premium Technique===
+
−
<br/>
+
−
Prime premium approach is based on the extra price (or profit) which a branded product may command over an unbranded or generic equivalent.
+
−
 
+
−
'''Volume  X Price premium = Brand Value'''
+
−
<br/><br/>
+
−
 
+
−
<div style="text-align: center;"><u>'''For Sanex Following are the details on which calculation was run'''</u></div><br/>
+
−
 
+
−
{|border="2" cellspacing="0" cellpadding="4" width="50%" align="center"
+
−
|bgcolor = "#4F81BD"|Brand
+
−
|bgcolor = "#4F81BD"|Price in GBP
+
 
|-
 
|-
−
|Local
+
|Revenue (Fiscal Year)
−
|align = "right"|0.73
+
|align = "right"|7,806
 
|-
 
|-
−
|SANEX
+
|Revenue Growth (1 yr)
−
|align = "right"|1.49
+
|align = "right"|(-4.70%)
 
|-
 
|-
−
|}
+
|Gross Profit
−
<br/>
+
|align = "right"|5,207
−
 
+
−
<div style="text-align: center;"><u>'''Total Sales of Sanex in Aerosol format'''</u></div><br/>
+
−
 
+
−
{|border="2" cellspacing="0" cellpadding="4" width="50%" align="center"
+
−
|bgcolor = "#8DB4E3"|Total  Deodorant Sales in Europe in USD
+
−
|align = "right" bgcolor = "#8DB4E3"|5,033.90M
+
 
|-
 
|-
−
|Total Spray Deodorant Sales in Europe in USD
+
|EBITDA
−
|align = "right"|2,885.30M
+
|align = "right"|1,859
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|% of Spray Sales / Total Sales
+
|bgcolor = "#002060" colspan = "2"|<font color="#FFFFFF">'''Trading Statistics (in $M)'''</font>
−
|align = "right" bgcolor = "#8DB4E3"|57.31
+
 
|-
 
|-
−
|Sales of Sanex Sprays in USD
+
|Market Capitalization
−
|align = "right"|109,641,400
+
|align = "right"|10,758.57
 
|-
 
|-
−
|}
+
|Shares Outstanding
−
<br/>
+
|align = "right"|1,528.21
−
 
+
−
<div style="text-align: center;"><u>'''Current Exchange Rate'''</u></div><br/>
+
−
 
+
−
{|border="2" cellspacing="0" cellpadding="4" width="50%" align="center"
+
−
|bgcolor = "#4F81BD"|Current Exchage Rate of 1 USD w.r.t GBP (as on 09/06/2011)
+
−
|align = "right" bgcolor = "#4F81BD"|0.61
+
 
|-
 
|-
−
|Current Exchage Rate of 1 GBP w.r.t USD (as on 09/06/2011)
+
|bgcolor = "#002060" colspan = "2"|<font color="#FFFFFF">'''Ratios'''</font>
−
|align = "right"|1.64
+
 
|-
 
|-
−
|}
+
|Current Ratio
−
<br/>
+
|align = "right"|1.75
−
 
+
−
<div style="text-align: center;"><u>'''Brand Value Calculations'''</u></div><br/>
+
−
 
+
−
{|border="2" cellspacing="0" cellpadding="4" width="50%" align="center"
+
−
|bgcolor = "#8DB4E3"|Sales of Sanex Sprays in GBP
+
−
|align = "right" bgcolor = "#8DB4E3"|66.88M
+
 
|-
 
|-
−
|Volume of Sales in Units = (Sales Value in GBP / Price of 1 Spray Bottle)
+
|P/E Ratio
−
|align = "right"|44.89M
+
|align = "right"|18.9
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|'''Brand Value = (Price Premium <nowiki>*</nowiki> Volume of Sales) in GBP'''
+
|Debt to Equity Ratio
−
|align = "right" bgcolor = "#8DB4E3"|'''34.11M'''
+
|align = "right"|43.31
−
|-
+
−
|'''Brand Value in USD'''
+
−
|align = "right"|'''55.92M'''
+
 
|-
 
|-
 
|}
 
|}
−
<br/>
 
−
&nbsp;
 
  
−
==Brand Positioning==
+
=====Segment contribution=====
−
[[image:11_22_1.JPG|thumb|800px|center|Deodorant Positioning in Europe]]
+
−
<u>'''Key Insights'''</u>
+
−
* The Position Map segments Deodorants on Three Parameters: Distinguishing Characteristics, Men/Women and Price Premium
+
−
* The Premiumness of Deodorants was calculated by considering the Median Retail Value of the top 14 Deodorant Brands of Western Europe as per the definition of a premium product by [http://http://www.businessdictionary.com/definition/premium-pricing.html/ Business Dictionary] is: "Practice in which a product is sold at a price higher that of competing brands to give it snob appeals through an aura of <nowiki>’</nowiki>exclusivity<nowiki>’</nowiki>"
+
−
* Most Deodorant Brands in Europe have different versions for Men and Women, by differentiating the products this way they have been able to capture a larger market share
+
  
−
 
+
{|border="2" cellspacing="0" cellpadding="4" width="53%"
−
&nbsp;
+
|align = "center" bgcolor = "#002060" colspan = "3"|<font color="#FFFFFF">'''Segment Contribution to the revenue (in $M)'''</font>
−
 
+
−
==Company Profile in Personal Care Market==
+
−
 
+
−
===Unilever===
+
−
 
+
−
====Strategic Evaluation====
+
−
 
+
−
=====Unilever Group=====
+
−
{|border="2" cellspacing="0" cellpadding="4" width="70%" align="center"
+
−
|bgcolor = "#4F81BD"|'''Name'''
+
−
|bgcolor = "#4F81BD"|'''Unilever Group'''
+
 
|-
 
|-
−
|bgcolor = "#DBE5F1"|Headquarter
+
|bgcolor = "#002060"|<font color="#FFFFFF">'''Segment'''</font>
−
|bgcolor = "#DBE5F1"|Netherlands,England & Wales
+
|bgcolor = "#002060"|<font color="#FFFFFF">'''Growth'''</font>
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Sales (2010)'''</font>
 
|-
 
|-
−
|Regionalinvolvement
+
|Cardiovascular
−
|WE, EE, LA, AP, MEA, AUS, NA
+
|align = "right"|(-5%)
 +
|align = "right"|811
 
|-
 
|-
−
|bgcolor = "#DBE5F1"|Leading categoryinvolvement
+
|Interventional Cardiology
−
|bgcolor = "#DBE5F1"|Deodorants,bath and shower, skin care
+
|align = "right"|(-8%)
 +
|align = "right"|635
 
|-
 
|-
−
|World beauty& personal care market share (2009)
+
|Peripheral Interventions
−
|6.8%
+
|align = "right"|7%
 +
|align = "right"|176
 
|-
 
|-
−
|bgcolor = "#DBE5F1"|Value growth (2008-2009)
+
|Coronary stent system
−
|bgcolor = "#DBE5F1"|7.6%
+
|align = "right"|(-7.9%)
 +
|align = "right"|409
 
|-
 
|-
−
|}
+
|Cardiac Rhythm Management
−
<br/>
+
|align = "right"|4%
−
 
+
|align = "right"|559
−
=====Key Strategies and Operations=====
+
−
 
+
−
1. '''Invest in Basic Products - '''Unilever is a global leader in categories which are generally described as commodities -examples include deodorants, bath and shower, shampoos and conditioners. Moving on, as the economic situation improves, these categories continue to have benefits as they have a much wider appeal for consumers in emerging markets.
+
−
 
+
−
2. '''Leverage Economies of Scale - '''Unilever has consolidated its operations in terms of manufacturing, procurement and other relevant activities and intends to take full advantage of this. It aims to invest in products that can work globally rather than just in a few countries.
+
−
 
+
−
3. '''Maintain Diversity - '''Unilever intends to focus on basic products that work globally, it still wants to maintain a diverse portfolio to accommodate different market conditions.
+
−
 
+
−
4. '''Increased Competition - '''While Unilever has performed well with its compact and focused approach to growth, it faces increased competition in the market. L<nowiki>’</nowiki>Oréal and Beiersdorf are identifying areas such as deodorants and body care, overlapping with Unilever. Moreover, Unilever faces competition from more competitively-priced private label.
+
−
<br/><br/>
+
−
 
+
−
====Competitive Positioning====
+
−
 
+
−
{|border="2" cellspacing="0" cellpadding="4" width="70%" align="center"
+
−
|bgcolor = "#4F81BD"|'''Company name'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2005'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2006'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2007'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2008'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2009'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2009 % share'''
+
 
|-
 
|-
−
|Procter & Gamble
+
|Defibrillators
−
|align = "Center"|1
+
|align = "right"|6.9%
−
|align = "Center"|1
+
|align = "right"|417
−
|align = "Center"|1
+
−
|align = "Center"|1
+
−
|align = "Center"|1
+
−
|align = "Center"|11.7
+
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|L<nowiki>’</nowiki>Oréal Groupe
+
|Pacemakers
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
|align = "right"|(-4%)
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
|align = "right"|142
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
−
|align = "Center" bgcolor = "#8DB4E3"|10.1
+
 
|-
 
|-
−
|'''Unilever Group'''
+
|Electrophysiology
−
|align = "Center"|'''3'''
+
|align = "right"|(-3%)
−
|align = "Center"|'''3'''
+
|align = "right"|37
−
|align = "Center"|'''3'''
+
−
|align = "Center"|'''3'''
+
−
|align = "Center"|'''3'''
+
−
|align = "Center"|'''6.8'''
+
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|Colgate-Palmolive Co
+
|Endoscopy
−
|align = "Center" bgcolor = "#8DB4E3"|4
+
|align = "right"|(-3%)
−
|align = "Center" bgcolor = "#8DB4E3"|4
+
|align = "right"|287
−
|align = "Center" bgcolor = "#8DB4E3"|4
+
−
|align = "Center" bgcolor = "#8DB4E3"|4
+
−
|align = "Center" bgcolor = "#8DB4E3"|4
+
−
|align = "Center" bgcolor = "#8DB4E3"|3.7
+
 
|-
 
|-
−
|Avon Products
+
|Urology/Women<nowiki>’</nowiki>s health
−
|align = "Center"|6
+
|align = "right"|10%
−
|align = "Center"|6
+
|align = "right"|120
−
|align = "Center"|6
+
−
|align = "Center"|5
+
−
|align = "Center"|5
+
−
|align = "Center"|3.4
+
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|Beiersdorf AG
+
|Neuromodulation
−
|align = "Center" bgcolor = "#8DB4E3"|7
+
|align = "right"|14%
−
|align = "Center" bgcolor = "#8DB4E3"|7
+
|align = "right"|77
−
|align = "Center" bgcolor = "#8DB4E3"|7
+
−
|align = "Center" bgcolor = "#8DB4E3"|6
+
−
|align = "Center" bgcolor = "#8DB4E3"|6
+
−
|align = "Center" bgcolor = "#8DB4E3"|3.3
+
−
|-
+
−
|Estée Lauder
+
−
|align = "Center"|5
+
−
|align = "Center"|5
+
−
|align = "center"|5
+
−
|align = "center"|7
+
−
|align = "center"|7
+
−
|align = "center"|3.1
+
−
|-
+
−
|bgcolor = "#8DB4E3"|Johnson & Johnson
+
−
|align = "center" bgcolor = "#8DB4E3"|9
+
−
|align = "center" bgcolor = "#8DB4E3"|8
+
−
|align = "center" bgcolor = "#8DB4E3"|8
+
−
|align = "center" bgcolor = "#8DB4E3"|8
+
−
|align = "center" bgcolor = "#8DB4E3"|8
+
−
|align = "center" bgcolor = "#8DB4E3"|2.9
+
−
|-
+
−
|Shiseido Co
+
−
|align = "center"|8
+
−
|align = "center"|9
+
−
|align = "center"|9
+
−
|align = "center"|9
+
−
|align = "center"|9
+
−
|align = "center"|2.5
+
 
|-
 
|-
 
|}
 
|}
−
<br/>
 
  
−
[[Image:competitive positioning1.png|centre|thumb|838×287px]]
+
Boston Scientific derives maximum contribution from Cardiovascular, which recorded a 5% year-over-year decline in sales to $811 million. While sales from Interventional Cardiology declined 8% to $635 million, Peripheral Interventions increased 7% to $176 million. Global sales of coronary stent system (within Interventional Cardiology) at $409 million declined 7.9% driven by lower sales of both drug-eluting stents (DES, 6.9% to $379 million) and bare-metal stents (18.9% to $30 million). It is encouraging to note that the company maintained its leadership position in the global DES market with 36% share and 46% in the US market.
 +
 
 +
The next biggest contributor to Boston Scientific<nowiki>’</nowiki>s top line, Cardiac Rhythm Management, recorded a 4% increase in sales to $559 million. A 6.9% rise in defibrillators sales to $417 million coupled with a 4% decline in sales of pacemakers to $142 million contributed to the overall increase.
 +
 
 +
Hence, the overall revenue of Boston Scientific declined by 4.7%. ([http://seekingalpha.com/article/264756-boston-scientific-boosts-bottom-line-despite-revenue-decline Seekingalpha.com])
 +
 
 +
====Revenue Distribution of Boston Scientific====
 +
=====By Product Category=====
  
−
====Market Assessment====
+
[[Image:revenue - productwise - Boston scientific.jpg]]
−
=====Unilever<nowiki>’</nowiki>s Deodorants Share Grows=====
+
−
* Unilever is by far the market leader in deodorants, with an over 31% global share in 2009. The company<nowiki>’</nowiki>s closest competitor is Procter & Gamble, with a 10% share.
+
−
* In the US, its largest deodorants market, Unilever launched four new deodorants each supported by substantial media advertising, marketing campaigns and promotions.
+
−
* Unilever has captured the deodorants market by offering interesting products, a slew of launches and products that appeal to a wider consumer group, supported by heavy investment in advertising and marketing.
+
−
* The markets to lead growth in absolute terms for deodorants are Brazil, Germany and India, all of which are led by Unilever, and the company is in a good position to benefit from the growth opportunities
+
−
* Unilever is the market leader and its position is unchallenged, but strategic moves by its competitors could put the company under strong threat.
+
−
* Deodorants is a strong category for Unilever and it should continue to spend on product development to beat the competition and keep its strong category leadership.
+
−
<br/>
+
  
−
[[Image:M_0988.JPG|924×345|center]]
+
The graph clearly shows the declining cardiovascular market, which constitutes the major part of Boston Scientific<nowiki>’</nowiki>s revenue. It gives a strong signal to the company to diversify its business into other business units and not be very dependent on one market.
−
<br/>
+
  
−
=====Category and Geographic Opportunity=====
+
=====By Geography=====
 +
[[Image:revenue - geogwise - Boston scientific.jpg]]
  
−
* Deodorants is Colgate-Palmolive<nowiki>’</nowiki>s fourth largest category in beauty and personal care, but the company<nowiki>’</nowiki>s sales are predominantly derived from the US market, at nearly 30% of its global category sales. However, the US is projected to grow only marginally, by US$51 million, over 2009-2014 compared to US$548 million for Brazil, the highest in the world.
+
<nowiki>*</nowiki>EMEA – Europe, Middle East and Africa
−
* The two other leading markets to drive growth are Germany and India, where Colgate-Palmolive does not a significant presence.
+
−
* Deodorants is projected to post robust growth and a few companies in the industry are expanding their presence in this category with the launch of products with additional features or breakthrough technology. Both Beiersdorf and L<nowiki>’</nowiki>Oréal have launched deodorants within the natural/organic niche, but Beiersdorf has gone a step further stating that it has formulated a technology to control stress-induced sweat with its deodorants. Strong product launches combined with effective marketing campaigns can ease the competitive pressure for Colgate-Palmolive.
+
−
&nbsp;
+
  
−
===Colgate===
+
The graph clearly shows that U.S. contributes to more than 50% of the company<nowiki>’</nowiki>s revenues. It shows an opportunity for the company to expand in other markets. They have started selling their products in Japan, which has already started contributing majorly to the revenues.
  
−
====Strategic Evaluation====
+
===Business Overview===
 +
====Product Portfolio====
  
−
=====Colgate Palmolive Co=====
+
{|border="2" cellspacing="0" cellpadding="4" width="100%"
−
{|border="2" cellspacing="0" cellpadding="4" width="70%" align="center"
+
|align = "center" bgcolor = "#002060" colspan = "5"|<font color="#FFFFFF"><font size = "4">'''Product Portfolio of Boston Scientific'''</font></font>
−
|bgcolor = "#4F81BD"|'''Name'''
+
−
|bgcolor = "#4F81BD"|'''Colgate Palmolive'''
+
 
|-
 
|-
−
|bgcolor = "#DBE5F1"|Headquarters
+
|bgcolor = "#002060"|<font color="#FFFFFF">'''Cardiovascular Group'''</font>
−
|bgcolor = "#DBE5F1"|New York, USA
+
|bgcolor = "#002060"|<font color="#FFFFFF">'''Cardiac Rhythm Management'''</font>
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Endoscopy'''</font>
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Urology and Women<nowiki>’</nowiki>s Health'''</font>
 +
|bgcolor = "#002060"|<font color="#FFFFFF">'''Neuromodulation'''</font>
 
|-
 
|-
−
|Regional Involvement
+
|Drug-Eluting Stents
−
|Global
+
|Remote Patient Management
 +
|Biliary Devices
 +
|Stone Management
 +
|Spinal Cord Stimulation
 
|-
 
|-
−
|bgcolor = "#DBE5F1"|Category Involvement
+
|Coronary Balloons
−
|bgcolor = "#DBE5F1"|Oral care, bathand shower, hair care, deodorants, men<nowiki>’</nowiki>s grooming, baby care
+
|Pacemakers
 +
|Cholangioscopy
 +
|Benign Prostatic Hyperplasia
 +
|  
 
|-
 
|-
−
|World Beauty and Personal Care value share (2009)
+
|Coronary Atherectomy
−
|3.7%
+
|Implantable Cardioverter Defibrillators
 +
|Biliary Stents
 +
|Pelvic Floor Reconstruction
 +
|  
 
|-
 
|-
−
|bgcolor = "#DBE5F1"|World Beauty and Personal Care value growth (2009)
+
|Embolic Protection
−
|bgcolor = "#DBE5F1"|6.1%
+
|Cardiac Resynchronization
 +
|Gastrointestinal Stents
 +
|Abnormal Uterine Bleeding
 +
|  
 
|-
 
|-
−
|}
+
|Inflation Devices
−
<br/>
+
|Therapy Defibrillators
−
 
+
|Tissue Acquisition
−
=====Key Strategies and Operations=====
+
|  
−
 
+
|  
−
1. '''International expansion - '''Colgate-Palmolive<nowiki>’</nowiki>s success in building a strong emerging market profile has helped its oral, personal and home care business weather the global financial storm, at least to date.
+
−
 
+
−
2. '''Product innovation based on scientific study - '''As part of its <nowiki>’</nowiki>winning on the ground<nowiki>’</nowiki> strategy, Colgate-Palmolive aims to combat the threat from private label at a time when consumers are trading down through a greater focus on product development close to consumer needs.
+
−
 
+
−
3. '''Strong marketing focus - '''Colgate-Palmolive<nowiki>’</nowiki>s strategy is to combine product development with strong marketing initiatives, across the globe.
+
−
 
+
−
4. '''Product offering at different pricing tiers - '''While the focus is on premium products, Colgate-Palmolive also aims to offer a range of products at a lower pricing tier –in case consumers are looking to trade down.
+
−
<br/><br/>
+
−
 
+
−
====Competitive Positioning====
+
−
 
+
−
{|border="2" cellspacing="0" cellpadding="4" width="70%" align="center"
+
−
|bgcolor = "#4F81BD"|'''Company name'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2005'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2006'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2007'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2008'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2009'''
+
−
|align = "Center" bgcolor = "#4F81BD"|'''2009 % share'''
+
 
|-
 
|-
−
|Procter & Gamble
+
|Peripheral Balloons
−
|align = "Center"|1
+
|Cardiac Resynchronization
−
|align = "Center"|1
+
|Gastrointestinal Bleeding
−
|align = "Center"|1
+
|  
−
|align = "Center"|1
+
|  
−
|align = "Center"|1
+
−
|align = "Center"|11.7
+
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|L<nowiki>’</nowiki>Oréal Groupe
+
|Interventional Oncology
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
|Therapy Pacemakers
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
|Balloon Dilatation
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
|  
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
|  
−
|align = "Center" bgcolor = "#8DB4E3"|2
+
−
|align = "Center" bgcolor = "#8DB4E3"|10.1
+
 
|-
 
|-
−
|Unilever Group
+
|Guide Wires
−
|align = "Center"|3
+
|Electrophysiology
−
|align = "Center"|3
+
|Pulmonary Devices
−
|align = "Center"|3
+
|  
−
|align = "Center"|3
+
|  
−
|align = "Center"|3
+
−
|align = "Center"|6.8
+
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|'''Colgate-Palmolive Co'''
+
|Diagnostic Catheters
−
|align = "Center" bgcolor = "#8DB4E3"|'''4'''
+
|Ablation Catheters
−
|align = "Center" bgcolor = "#8DB4E3"|'''4'''
+
|Airway Stents
−
|align = "Center" bgcolor = "#8DB4E3"|'''4'''
+
|  
−
|align = "Center" bgcolor = "#8DB4E3"|'''4'''
+
|  
−
|align = "Center" bgcolor = "#8DB4E3"|'''4'''
+
−
|align = "Center" bgcolor = "#8DB4E3"|'''3.7'''
+
 
|-
 
|-
−
|Avon Products
+
|Guide Catheters
−
|align = "Center"|6
+
|Intracardiac Echocardiography
−
|align = "Center"|6
+
|Bronchial Thermoplasty
−
|align = "Center"|6
+
|  
−
|align = "Center"|5
+
|  
−
|align = "Center"|5
+
−
|align = "Center"|3.4
+
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|Beiersdorf AG
+
|Intravascular Ultrasound
−
|align = "Center" bgcolor = "#8DB4E3"|7
+
|Diagnostic Catheters
−
|align = "Center" bgcolor = "#8DB4E3"|7
+
|  
−
|align = "Center" bgcolor = "#8DB4E3"|7
+
|  
−
|align = "Center" bgcolor = "#8DB4E3"|6
+
|  
−
|align = "Center" bgcolor = "#8DB4E3"|6
+
−
|align = "Center" bgcolor = "#8DB4E3"|3.3
+
 
|-
 
|-
−
|Estée Lauder
+
|Vascular Access/Chronic Total Occlusion
−
|align = "Center"|5
+
|  
−
|align = "Center"|5
+
|  
−
|align = "center"|5
+
|  
−
|align = "center"|7
+
|  
−
|align = "center"|7
+
−
|align = "center"|3.1
+
 
|-
 
|-
−
|bgcolor = "#8DB4E3"|Johnson & Johnson
+
|Peripheral Stents
−
|align = "center" bgcolor = "#8DB4E3"|9
+
|  
−
|align = "center" bgcolor = "#8DB4E3"|8
+
|  
−
|align = "center" bgcolor = "#8DB4E3"|8
+
|  
−
|align = "center" bgcolor = "#8DB4E3"|8
+
|  
−
|align = "center" bgcolor = "#8DB4E3"|8
+
−
|align = "center" bgcolor = "#8DB4E3"|2.9
+
−
|-
+
−
|Shiseido Co
+
−
|align = "center"|8
+
−
|align = "center"|9
+
−
|align = "center"|9
+
−
|align = "center"|9
+
−
|align = "center"|9
+
−
|align = "center"|2.5
+
 
|-
 
|-
 
|}
 
|}
−
<br/>
 
−
 
−
 
−
[[Image:competitive_positioning.png|thumb|centre|860×553px]]
 
−
 
−
=====Global Consolidation=====
 
−
[[Image:global consolidation.png|thumb|centre|386×580px]]
 
−
<br/>
 
−
 
−
====Market Assessment====
 
−
 
−
*Colgate-Palmolive is too focused on oral care, which generates around 63% of its total revenue. While the company is the global leader in oral care, with nearly a quarter of value sales, oral care is also one of the most mature categories with its percentage growth projection below that of the industry average over 2009-2014.
 
−
 
−
*Its three other categories following oral care are bath and shower, hair care and deodorants, respectively. Colgate-Palmolive has a good presence in Brazil bath and shower, one of the markets to drive growth in this category, but has yet to penetrate China and India, two other strategic markets to drive absolute growth in bath and shower.
 
−
 
−
*Colgate-Palmolive will also benefit from expanding in deodorants, which has a robust growth projection. Competitive pressure is strong with not only Unilever controlling the market, but also players, such as Beiersdorf and L<nowiki>’</nowiki>Oréal, making the category their key priority.
 
−
<br/>
 
−
<br/>
 
−
 
−
====Category and Geographic Opportunity====
 
−
 
−
* Deodorants is Colgate-Palmolive<nowiki>’</nowiki>s fourth largest category in beauty and personal care, but the company<nowiki>’</nowiki>s sales are predominantly derived from the US market, at nearly 30% of its global category sales. However, the US is projected to grow only marginally, by US$51 million, over 2009-2014 compared to US$548 million for Brazil, the highest in the world.
 
−
* The two other leading markets to drive growth are Germany and India, where Colgate-Palmolive does not a significant presence.
 
−
* Deodorants is projected to post robust growth and a few companies in the industry are expanding their presence in this category with the launch of products with additional features or breakthrough technology. Both Beiersdorf and L<nowiki>’</nowiki>Oréal have launched deodorants within the natural/organic niche, but Beiersdorf has gone a step further stating that it has formulated a technology to control stress-induced sweat with its deodorants. Strong product launches combined with effective marketing campaigns can ease the competitive pressure for Colgate-Palmolive.
 
−
<br/><br/>
 
−
[[Image:deo_growth.png|thumb|centre|804×261px]]
 
  
−
===Competitors===
+
====Geographical Presence====
−
<br/>
+
The Corporate headquarters of Boston Scientific is in Natick, Massachusetts. The company is present in the following locations in Europe/Middle East/Africa, America and Asia Pacific/Japan.
  
−
====L'Oreal Inc====
+
{|border="2" cellspacing="0" cellpadding="4" width="55%"
−
<br/>
+
|align = "justify" bgcolor = "#002060"|<font color="#FFFFFF">'''Europe/Middle East/Africa'''</font>
−
{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"
+
|align = "justify" bgcolor = "#002060"|<font color="#FFFFFF">'''America'''</font>
−
|align = "justify" bgcolor = "#4F81BD"|<u>Parameters</u>
+
|align = "justify" bgcolor = "#002060"|<font color="#FFFFFF">'''Asia Pacific/Japan'''</font>
−
|align = "center" bgcolor = "#4F81BD"|<u>Details</u>
+
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Overview'''</font>
+
|align = "justify"|Austria
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* L<nowiki>’</nowiki>Oreal is world<nowiki>’</nowiki>s largest beauty products company, it creates makeup, perfume, and hair and skin care items<br>* L<nowiki>’</nowiki>Oreal has a century of expertise in cosmetics with  €19.5 billion consolidated sales in 2010<br>* L<nowiki>’</nowiki>Oreal 23 global brands across  130 countries<br>* L<nowiki>’</nowiki>Oreal filed 612 patents filed in 2010</font>
+
|align = "justify"|Argentina
 +
|align = "justify"|New Zealand
 
|-
 
|-
−
|align = "justify"|'''Business Segments'''
+
|align = "justify"|Belgium
−
|align = "justify"|* '''''Consumer Products:''''' High technology products at competitive price are distributed through mass-market retailing channels (Garnier, L<nowiki>’</nowiki>Oréal Paris, Maybelline NY, Softsheen-Carson)<br>* '''''Professional Products''''': Portfolio of brands that meet the requirements of hair salons (L<nowiki>’</nowiki>Oréal Professionnel, Kérastase, Redken, Matrix, Mizani, Shu Uemura Art of Hair, Keraskin Esthetics)<br>* '''''Active Cosmetics:''''' Dermo-cosmetics products sold in pharmacies and specialist retailers and supported by advice from pharmacists and dermatologists (Vichy, La Roche-Posay, Innéov, Skinceuticals, Sanoflore)<br>* '''''The Body Shop:''''' Naturally inspired and fairly traded products sold in over 2300 The Body Shop stores throughout the world
+
|align = "justify"|Brazil
 +
|align = "justify"|China
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Geographic Presence'''</font>
+
|align = "justify"|Czech Republic
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* The company currently has operations in over 130 countries across five continents</font>
+
|align = "justify"|Canada
 +
|align = "justify"|Hong Kong
 
|-
 
|-
−
|align = "justify"|'''Brands'''
+
|align = "justify"|Denmark
−
|align = "justify"|* L<nowiki>’</nowiki>Oréal Paris, Garnier, Maybelline New York, Softsheen, Carson, CCB Paris, L<nowiki>’</nowiki>Oreal Professionel, Kerastase, and Redke, etc.
+
|align = "justify"|Chile
 +
|align = "justify"|India
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Revenue'''</font>
+
|align = "justify"|Finland
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* €19.50 billion (2010)</font>
+
|align = "justify"|Colombia
 +
|align = "justify"|Korea
 
|-
 
|-
−
|align = "justify"|'''Profit'''
+
|align = "justify"|France
−
|align = "justify"|* €2.240 billion (2010)
+
|align = "justify"|Costa Rica
 +
|align = "justify"|Tokyo
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Recent Developments'''</font>
+
|align = "justify"|Germany
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* L<nowiki>’</nowiki>Oreal announces the reunification of the roles of Chairman of the Board of Directors and Chief Executive Officer of the Group. Jean-Paul Agon was appointed the Chairman and CEO Sir Lindsay Owen-Jones Honorary Chairman</font>
+
|align = "justify"|Mexico
 +
|align = "justify"|<font color="#333333">Fukuoka</font>
 
|-
 
|-
−
|}<br clear="all">
+
|align = "justify"|Greece
−
 
+
|align = "justify"|Uruguay
−
====Beiersdorf AG====
+
|align = "justify"|<font color="#333333">Hiroshima</font>
−
<br/>
+
−
{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"
+
−
|align = "justify" bgcolor = "#4F81BD"|<u>Parameters</u>
+
−
|align = "center" bgcolor = "#4F81BD"|<u>Details</u>
+
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Overview'''</font>
+
|align = "justify"|Hungary
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* Beiersdorf Aktiengesellschaft engages in the development, manufacture, and marketing of consumer goods in Europe, the Americas, Africa, Asia, and Australia<br>* It is based out of Hamburg, Germany</font>
+
|align = "justify"|Venezuela
 +
|align = "justify"|<font color="#333333">Kanagawa </font>
 
|-
 
|-
−
|align = "justify"|'''Business Segments'''
+
|align = "justify"|Ireland
−
|align = "justify"|* '''''Consumer Business segment:''''' It offers skin and beauty care products<br>* '''''Tesa Business segment: '''''It manufactures and sells self-adhesive systems and product solutions for industrial customers and consumers
+
|align = "justify"|West Indies
 +
|align = "justify"|<font color="#333333">Ishikawa</font>
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Geographic Presence'''</font>
+
|align = "justify"|Israel
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* Company operates wholly owned subsidiaries in Germany, Austria, the Czech Republic, Switzerland, Poland, Russia, Hungary, Mexico, the United States, Canada, Brazil, Japan, Singapore, and the United Arab Emirates</font>
+
|align = "justify"|Massachusetts
 +
|align = "justify"|<font color="#333333">Saitama </font>
 
|-
 
|-
−
|align = "justify"|'''Brands'''
+
|align = "justify"|Italy
−
|align = "justify"|* Nivea, Eucerin, La Parairie, Florena, Slek, SBT & Hansaplast, etc.
+
|align = "justify"|California
 +
|align = "justify"|<font color="#333333">Miyazaki</font>
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Revenue'''</font>
+
|align = "justify"|Lebanon
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* €6.194 billion (2010)</font>
+
|align = "justify"|Florida
 +
|align = "justify"|<font color="#333333">Aichi </font>
 
|-
 
|-
−
|align = "justify"|'''Profit'''
+
|align = "justify"|Netherlands
−
|align = "justify"|* €318 million (2010)
+
|align = "justify"|Indiana
 +
|align = "justify"|<font color="#333333">Osaka </font>
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Recent Developments'''</font>
+
|align = "justify"|Norway
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* NIVEA brand recently completed "100 Years Skincare for Life".<br>* Focus on Skin Care, closer to Markets<nowiki>’</nowiki> strategy is designed to make the company even more competitive<br>* Focus its resources in selective skin care markets<br>* Global streamlining & harmonization of product portfolio by substantial investments in the company<nowiki>’</nowiki>s skin and body care brands<br>* Beiersdorf appointed Peter Feld, formerly General Manager of Johnson & Johnson GmbH Germany, as  the new Executive Board member</font>
+
|align = "justify"|Minnesota
 +
|align = "justify"|<font color="#333333">Hokkaido</font>
 
|-
 
|-
−
|}<br clear="all">
+
|align = "justify"|Poland
−
 
+
|align = "justify"|Utah
−
====Henkel AG & Co KGaA====
+
|align = "justify"|<font color="#333333">Miyagi </font>
−
<br/>
+
−
{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"
+
−
|align = "justify" bgcolor = "#4F81BD"|<u>Parameters</u>
+
−
|align = "center" bgcolor = "#4F81BD"|<u>Details</u>
+
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Overview'''</font>
+
|align = "justify"|Portugal
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* Henkel was founded in 1876<br>* The Dax-30 company is headquartered in Düsseldorf, Germany, and ranked among the Fortune Global 500<br>* Henkel employs 48,000 people worldwide, 80 percent of which work outside of Germany. Henkel is one of the most internationally aligned German companies</font>
+
|align = "justify"|Washington
 +
|align = "justify"|<font color="#333333">Kanagawa </font>
 
|-
 
|-
−
|align = "justify"|'''Business Segments'''
+
|align = "justify"|Spain
−
|align = "justify"|* '''''Laundry & Home Care:''''' The laundry products comprise heavy-duty detergents and special detergents. In fiscal 2010, the Laundry & Home Care business sector contributed 29 % of total company sales<br>* '''''Cosmetics / Toiletries''':'' Schwarzkopf & Henkel stands for brand-name products in the fields of hair colorants, hair styling hair care and form, toiletries, skin care and oral hygiene. Schwarzkopf Professional is one of the world<nowiki>’</nowiki>s leading suppliers of hair salon products. In fiscal 2009, the segment contributed 22 % of total company sales<br>* '''''Adhesive Technologies:''''' Henkel is the world market leader in adhesives, sealants and surface treatments for consumers, craftsmen and industrial applications. Henkel offers a multitude of applications to satisfy the needs of different target groups – consumers as well as craftsmen and industrial businesses. In fiscal 2009, the business sector contributed 48 % of total company sales
+
|align = "justify"|  
 +
|align = "justify"|Malaysia
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Geographic Presence'''</font>
+
|align = "justify"|South Africa
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* With presence in 125 countries on five continents, Henkel engages in the majority of its business within Europe and North America</font>
+
|align = "justify"|  
 +
|align = "justify"|Philippines
 
|-
 
|-
−
|align = "justify"|'''Brands'''
+
|align = "justify"|Sweden
−
|align = "justify"|* Persil<sup> </sup>washing powder, Spee washing powder, Vernel/Silan fabric softener, Somat/Glist dishwasher tablets, Pril washing-up liquid, Schwarzkopf hair care, Schauma shampoo, Fa shower gel and deodorant, Diadermine skin and body care, Dial shower and hand soap, Loctite adhesives, etc.
+
|align = "justify"|  
 +
|align = "justify"|Singapore
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Revenue'''</font>
+
|align = "justify"|Switzerland
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* €15,092 million (2010)</font>
+
|align = "justify"|  
 +
|align = "justify"|Taiwan
 
|-
 
|-
−
|align = "justify"|'''Profit'''
+
|align = "justify"|Turkey
−
|align = "justify"|* €1,862 million (2010)
+
|align = "justify"|  
 +
|align = "justify"|Thailand
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Recent Developments'''</font>
+
|align = "justify"|United Kingdom
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* '''''Mar 2011:''''' Henkel was recognized with the European Diversity Leadership Honour Award in the Multicultural Working Environment category, the jury was particularly impressed by the company<nowiki>’</nowiki>s commitment and transparency in the diversity domain<br>* '''''Feb 2011:''''' Henkel unveiled new company logo and slogan <nowiki>’</nowiki>Henkel – Excellence is our Passion<nowiki>’</nowiki>.<br>* '''''Jan 2011:''''' Henkel conferred "Best Supply Performance 2010" award to Firmenich and Symrise for their outstanding operational supply performance<br>* '''''Aug 2010:''''' CMO at Henkel Müller, responsible for the global retail business of the company<nowiki>’</nowiki>s hair cosmetics, skin and oral care segments, was awarded the accolade of "Chief Marketing Officer of the Year", in recognition of outstanding and innovative marketing achievements that have made a major contribution to corporate success</font>
+
|align = "justify"|  
 +
|align = "justify"|  
 
|-
 
|-
−
|}<br clear="all">
+
|}
 +
 
 +
====Organization Structure====
 +
[[Image:Organization Structure of Boston Scientific.jpg]]
 +
([http://www.theofficialboard.com/org-chart/boston-scientific Theofficialboard.com])
 +
 
 +
'''Key Executives'''
 +
 
 +
* Chairman: Peter M. (Pete) Nicholas
 +
* EVP and COO: Samuel R. (Sam) Leno
 +
* EVP and CFO: Jeffrey D. (Jeff) Capello
 +
 
 +
===Market Overview===
 +
====Market Share====
 +
[[Image:Market Share - Medical Devices (2010).jpg]]
  
−
====Procter & Gamble Co.====
+
====Top 10 companies in the medical devices industry====
−
<br/>
+
{|border="2" cellspacing="0" cellpadding="4" width="44%"
−
{|border="2" cellspacing="0" cellpadding="4" width="80%" align="center"
+
|bgcolor = "#002060"|<font color="#FFFFFF">'''Top 10 companies in the medical devices industry'''</font>
−
|align = "justify" bgcolor = "#4F81BD"|<u>Parameters</u>
+
|bgcolor = "#002060"|<font color="#FFFFFF">'''Sales in 2010 ($B)'''</font>
−
|align = "center" bgcolor = "#4F81BD"|<u>Details</u>
+
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Overview'''</font>
+
|Johnson & Johnson
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* The Procter & Gamble Company was founded in 1837 and is headquartered in Cincinnati, Ohio.<br>* P&G world<nowiki>’</nowiki>s largest multinational consumer goods company, Procter & Gamble Co. (P&G, NYSE: PG) is the 4th largest corporation in the world by market capitalization and is Fortune<nowiki>’</nowiki>s 6th Most Admired Company.<br>* P&G touches the lives of 4 billion consumers daily with trusted brands</font>
+
|align = "right"|23.60
 
|-
 
|-
−
|align = "justify"|'''Business Segments'''
+
|Siemens Healthcare
−
|align = "justify"|* '''''Beauty and Grooming: '''''GBU offers female beauty products, including cosmetics, deodorants, female blades and razors, personal cleansing and skin care products, hair care products, and fragrances under the Head & Shoulders, Olay, Pantene, and Wella brands. It also provides electric hair removal devices, home appliances, male blades and razors, and male personal care products, such as deodorants, face and shave products, hair care, and personal cleansing products under the Braun, Fusion, Gillette, and Mach3 brands<br>* '''''Health and Well-Being:''''' GBU provides feminine care, oral care, and personal health care products under Always, Crest, and Oral-B brands; and snacks and pet food under the Lams and Pringles brands<br>* '''''Household Care:''''' GBU offers air care products, batteries, dish care products, and fabric care and surface care products under the Ace, Ariel, Dawn, Downy, Duracell, Gain, and Tide brands. It also offers baby care and family care products, under the Bounty, Charmin, and Pampers brands<br>* '''''Retail & Brands:''''' P&G sells its products through retail operations, including mass merchandisers, grocery stores, membership club stores, drug stores, department stores, salons, and high-frequency stores
+
|align = "right"|17.40
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Geographic Presence'''</font>
+
|GE Healthcare
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* P&G products are available in North America, Latin America, Europe, the Middle East, Africa, Asia, Australia and New Zealand</font>
+
|align = "right"|16.00
 
|-
 
|-
−
|align = "justify"|'''Brands'''
+
|Medtronic
−
|align = "justify"|* Tide, Olay, Pantene, Herbal Essences, Gillette, Always, Pampers, Crest, Braun, Pringles, Duracell, Secret, Old Spice, Hugo Boss, etc.
+
|align = "right"|15.82
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Revenue'''</font>
+
|Baxter International
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* US$ 78.938 billion (2010)</font>
+
|align = "right"|12.60
 
|-
 
|-
−
|align = "justify"|'''Profit'''
+
|Philips Healthcare
−
|align = "justify"|* -
+
|align = "right"|11.20
 
|-
 
|-
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">'''Recent Developments'''</font>
+
|Abbott Laboratories
−
|align = "justify" bgcolor = "#DBE5F1"|<font color="#000000">* P&G signed a binding offer with the Sara Lee Corporation to acquire Ambi Pur for €320 million. Procter & Gamble acquired the high end shaving chain called the Art of Shaving in line with its objective to expand in high end male grooming category<br>* Procter & Gamble has sold of its hair care brands to reduce its exposure to slow-growing businesses<br>* P&G also decided to dispose off its pharma unit, but it seems it finding it difficult to find a buyer due to the credit crunch. Procter & Gamble organized its beauty and grooming business unit around "Him and Her" to better connect with the male consumer section which has not received the same level attention as female consumers</font>
+
|align = "right"|8.40
 
|-
 
|-
−
|}<br clear="all">
+
|Boston Scientific
 +
|align = "right"|8.00
 +
|-
 +
|Covidien
 +
|align = "right"|7.81
 +
|-
 +
|Becton Dickinson
 +
|align = "right"|7.16
 +
|-
 +
|}
  
−
==SWOT of Colgate==
+
====SWOT Analysis of Boston Scientific====
−
<br/>
+
−
[[image:colgate_swot.PNG|center]]
+
−
<br/>
+
−
&nbsp;
+
  
−
==LinkedIn Data Mining==
+
[[Image:SWOT - Boston Scientific.jpg]]
  
−
===Growth of Employees in Sales & Marketing and R&D===
+
===Transactional Activities===
−
[[image:6655_4.PNG|thumb|1153×415px|LinkedIn]]
+
  
−
===Insights for Unilever===
 
−
<br/>
 
−
[[Lateral Movement of Employees working in Unilever]]
 
−
<br/><br/>
 
−
<u>'''Key Insights'''</u>
 
−
* Unilever<nowiki>'</nowiki>s Growth in terms of Sales and Marketing is more than the Industry average, this justifies its high sales and Market Leadership position across various categories
 
−
* Unilever attracts talent from rival firms such as Kraft, Sara Lee, etc. However, after working in Unilever people generally go in for Consulting Organizations like Accenture, this shows the expertise they gain in the organization specifically in Supply Chain and Logistics
 
−
&nbsp;
 
  
−
===Insights for Colgate===
+
{|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"
−
<br/>
+
|bgcolor = "#002060" colspan = "4"|<font color="white"> <font size = "4">Mergers & Acquisitions done by Boston Scientific</font><br><font size = "4"> </font>  
−
[[Lateral Movement of Employees working in Colgate]]
+
|-
−
<br/><br/>
+
|bgcolor = "#0000"|<width="100%">|align = "right"|<font color="white"> '''Acquired Company'''
−
<u>'''Key Insights'''</u>
+
|bgcolor = "#0000"|<width="100%">|<font color="white"> '''Date'''
−
* Colgate spends quite less on R&D and hence prefers Acquisitions as preferred mode of expansion
+
|bgcolor = "#0000"|<width="100%">|<font color="white"> '''Value ($) M'''
−
* However, the striking feature here is the shrinking employee growth rate in Colgate in Sales and Marketing as compared to its competitors
+
|bgcolor = "#0000"|<width="100%">|<font color="white"> '''Reason for Acquisition'''
−
 
+
|-
−
&nbsp;
+
|<font color="#333333">Atritech Inc</font>
−
 
+
|align = "right"|<font color="#181818"> Jan-11 </font>  
−
===Insights for P&G===
+
|align = "right"|<font color="#181818">100</font>
−
<br/>
+
|* <font color="#181818">It strengthens the BS<nowiki>’</nowiki>s product offerings in the fast-growing areas of structural heart therapy</font><br>* <font color="#181818">Also a trial fibrillation, which represent two of their Priority Growth Initiatives.</font><br><font color="#181818">([http://www.alacrastore.com/mergers-acquisitions/Boston_Scientific_Corporation-1060228 Alacrastore.com])</font>
−
[[Lateral Movement of Employees working in P&G]]
+
|-
−
<br/><br/>
+
|<font color="#333333">ReVascular Therapeutics Inc</font>
−
<u>'''Key Insights'''</u>
+
|align = "right"|<font color="#333333"> Feb-11 </font>
−
* P&G's personnel growth in Sales and Marketing as well as R&D is quite less
+
|align = "right"|N/A
−
* An interesting trend is the movement of employees from P&G into Hewlett Packard which is a core Technology Firm, this shows strong Technology Adoption Culture being followed in P&G
+
|* These two novel technologies treat peripheral chronic total occlusions (CTOs).<br>* BSX made the acquisitions because the devices cover areas with promise of high growth potential. ([http://finance.yahoo.com/news/Boston-Scientific-Strengthens-prnews-2182311141.html?x=0&.v=1 Yahoo Finance])
−
&nbsp;
+
|-
−
 
+
|<font color="#333333">Intelect Medical Inc</font>
−
===Insights for Beiersdorf===
+
|align = "right"|Jan -11
−
<br/>
+
|align = "right"|78
−
[[Lateral Movement of Employees working in Beiersdorf]]
+
|* It supports BSX long-term strategy of enhancing the product portfolio and gaining market share in the Neuromodulation space<br>* It will help them to provide the most advanced deep brain stimulation technology solutions for neurologists, neurosurgeons and their patients.<br>* The GUIDE DBS system would be a major advance in deep brain stimulation therapy, especially when used in conjunction with BSX<nowiki>’</nowiki>s Vercise DBS System. ([http://www.massdevice.com/news/boston-scientific-adds-two-blocked-artery-treatment-devices-acquisitions-roundup Massdevice.com],  [http://blog.medicaldesign.com/perspectives/2011/02/16/ Medicaldesign.com])
−
<br/><br/>
+
|-
−
<u>'''Key Insights'''</u>
+
|<font color="#333333">Sadra Medical Inc</font>
−
* Beiersdorf has been steadily reducing Personnel growth in its R&D department, hinting at heightening M&A Activity
+
|align = "right"| Jan -11
−
&nbsp;
+
|align = "right"|193
−
 
+
|* Will Help BSX leverage on its clinical expertise and existing sales channels in the fast-growing area of structural heart therapy.( [http://www.reuters.com/article/2011/01/04/idUS196379+04-Jan-2011+PRN20110104 Reuters])
−
===Insights for Henkel===
+
|-
−
<br/>
+
|<font color="#333333">Asthmatx Inc</font>
−
[[Lateral Movement of Employees working in Henkel]]
+
|align = "right"|<font color="#333333"> Oct-10 </font>
−
<br/><br/>
+
|align = "right"|<font color="#333333">193.5</font>
−
<u>'''Key Insights'''</u>
+
|* <font color="#333333">Named as Top Ten Medical Innovations for 2007" by the Cleveland Clinic Foundation.</font><br>* <font color="#333333">The transaction is expected to provide meaningful revenue growth in the midterm ([http://www.asthmatx.com/news-events/press-releases/?i=450 Asthmatx.com])</font>
−
* Henkel has an increased spend in Research and Development Activities which shows that strategies are directed towards product innovations
+
|-
−
* The attrition rate is low, that shows that Henkel is trying its best to retain its employees and job satisfaction is high
+
|Labcoat Ltd . (Ireland)
−
&nbsp;
+
|align = "right"|Sep- 10
 +
|align = "right"|N/A
 +
|* The Technology represents a major advance for drug-eluting stents and would help BSX maintain their  strong position in this market ([http://bostonscientific.mediaroom.com/index.php?s=43&item=793 Bostonscientific])
 +
|-
 +
|Remon Medical Technologies Inc
 +
|align = "right"|Aug-07
 +
|align = "right"|. 73
 +
|* Provides BSX with innovative sensor and wireless communication technology that complements their Cardiac Rhythm Management product line.<br>* Also to maintain the leadership position ([http://salesandmarketingnetwork.com/news_release.php?ID=2015814 Salesandmarketingnetwork.com])
 +
|-
 +
| EndoTex Interventional Systems Inc .
 +
|align = "right"|Jan-07
 +
|align = "right"|142
 +
|* <font color="#333333">leadership in treating carotid artery disease ([http://uk.reuters.com/article/2007/01/04/bostonscientific-acquisition-idUKN0419620070104 Reuters])</font>
 +
|-
 +
| Guidant Corp
 +
|align = "right"|Apr-06
 +
|align = "right"|27000
 +
|* <font color="#333333">To be a global leader in cardiovascular devices ([http://www.cbsnews.com/stories/2006/01/25/business/main1236024.shtml Cbsnews])</font>
 +
|-
 +
|TriVascular
 +
|align = "right"|Apr-05
 +
|align = "right"|110
 +
|* To increase its share in the overall market for abdominal aortic aneurysms (AAA)device ([http://www.fdanews.com/newsletter/article?issueId=7456&articleId=71208 Fdanews])
 +
|-
 +
|}
  
−
==Recommendations==
+
===Roadmap===
 +
====Company<nowiki>’</nowiki>s focus on R&D====
 +
[[Image:Employees split-2.jpg]]
 +
[[Image:US Patents issued (Boston Scientific).jpg]]
 +
[[Image:R&D investment - Boston.jpg]]
  
−
[[Image:R_123.JPG|centre|642×300px]]
+
(Similar companies are based on the same industry and similar size for the year 2011)
  
−
===Key Geographies for Deodorant Market===
+
* The first chart shows the number of employees in the R&D department in Boston Scientific is 9% higher than the industry standards (in 2011). The other chart shows that over the span of 8 years (2002-2009), the investment by Boston Scientific in R&D has increased by 200%. Also, by the end of 2009, 7240 US patents have been granted to Boston Scientific and 10,009 patents are pending. It shows that Boston Scientific is clearly focused on investing in new technology through R&D.
−
<br/>
+
* In addition to the Company<nowiki>’</nowiki>s internal investments, Boston Scientific is committed to investing in external, or acquired, R&D through acquisitions and investments in new businesses.
−
====Western Europe====
+
* Boston Scientific in future is committed to developing less-invasive products and procedures, and through the acquisition of new technologies, to better enable physicians to treat their patients.
 +
* The sales force of Boston Scientific is 3% lower than the industry standards. This shows that the company has an established customer base that are loyal to the company and Boston Scientific does not have to push is products in the market.
  
−
* Germany – It has the highest spend per capita in the world for deodorants.  With a stable growth rate in the next 4 years, Germany remains an important place to have a presence. As Sanex already is there in Germany, with Uilever<nowiki>’</nowiki>s Sales and Marketing experience can take this brand even further ahead.
+
====Key Insights====
−
* UK – Next best country after Germany for spend per capita. Usage is very high and is a part of daily habit. This market is exploited by many big and small players but still keeps the scope of new entrants with new product innovations. As people are very aware and used to deodorant as a category, continues new ranges and product innovation is where lies the key.
+
* Boston Scientific continues to focus on strategic initiatives to drive growth and profitability. Till now USA has been the major geographical market for this company but Japan is emerging post 2008
−
<br/>
+
* Recent acquisitions made by the company along with promising new technologies are expected to boost the company's pipeline
 +
* Boston Scientifics' core businesses are witnessing significant pricing pressure and market decline.  Due to which the revenues have gone down by 4.70% for the fiscal year 2010.Moreover, the economic uncertainty is impacting its procedure volume.
 +
* The dependence on Cardiovascular segment is very high and cannot be ignored. As its witnessing several challenges including pricing pressure, intense competition and slower market growth leading to a decline ranging between 3-8% annually
  
−
====Eastern Europe====
+
* There are a few segments like urology/ women's health, neurovascular & Neuromodulation which have shown higher growth percentage that reaches up to 14% but the contribution of these segments is very low despite higher growth rate. Though this higher growth rate can be a signal of growth potential for future concentration of efforts
  
−
In Eastern Europe Colgate has its presence with Mennen and Palmolive deodorants. But with no new product innovation in last few years and very less spent on marketing, these brands were ignored to an extent by Colgate. As per a report published on Colgate acquiring Sanex, one major reason behind this acquisition was to get R&D capabilities in Deodorant market which Colgate lacked initially.
+
* Company needs to realign their business portfolio to improve leverage and accelerate profitable revenue growth. The Company's  diversification in Neuromodulation has been considered as a good decision by industry professionals
  
−
* Poland – Part of eastern market, which is growing at very high rate in the context of deodorants, Poland has the highest spend per capita, and an increasing projected value growth in deodorant markets.
+
* Co.  Faces certain industry risks such as failure of approval from FDA, approved devices being pulled from market due to safety reasons along with eroding market share and expiring patents. The recent example of pull back is the iCross Coronary Imaging Catheters
−
* Russia – Russia, because of the population is expected to have a high volume for deodorant sales, though it has low spend per capita, but the projected growth trend is stable and promising.
+
−
* Hungary – Expected to grow in next two years but may get stagnant after that because of very low spend per capita on deodorants
+
−
<br/>
+
  
−
===Consumer Insights===
+
* It's been noted that their long standing approach to growth is by strategic acquisitions of , investments in or alliances with other businesses or companies but the co. may not always be successful in generating growth this way
  
−
* Women still remain the driving point behind men using personal care items, thus the positioning should always be around attraction and sex appeal
+
* BSX needs to control costs, grow foreign market revenue and has to continue to get timely regulatory approvals.  Expansion of global sales and marketing focus is important along with Increasing its presence in markets such as China, India and Brazil and expanding the number of product registrations outside the U.S.
−
* One of the biggest turn off among women is men with dangling white residue from their underarms. No product in Europe till date is tackling this problem, and it can be treated as a new product innovation to invest into
+
−
* In Russia, preserving feminity is of  key importance, hence becomes the weak point to sell personal care products to Russian women
+
−
* Secondary research on consumer behavior insights will be backed by [[media:112233.docx|Primary Research]] in key European markets 
+
−
<br/>
+
  
−
===Brand Positioning===
+
* With respect to these declining figures new strategies need to be worked on, to either increase the contribution from this segment or diversify in to other segments
  
−
* The key challenge for Colgate is that the parent company Colgate Palmolive is considered as a brand and not as a parent company with umbrella brands.
+
===Contact===
−
* Nine out of ten people consider Colgate as an Oral care brand and not as a personal care brand.
+
−
*  As Oral care market is almost saturated and with Colgate having plans in exploring more categories, it becomes even more challenging.
+
−
* Branding its individual brands separately is the biggest challenge Colgate is facing, the marketing attempts should be more focused to strengthening the Individual brands, being distributed by Colgate Palmolive, like in the case of P&G, Unilever and Reckitt.
+
−
* Colgate is known for its continues innovations, and now after acquiring Sanex R&D Capablties, Colgate can explore newer markets and also can strengthen its existing brand – Mennen and Palmolive.
+
−
<br/>
+
−
Tough Sanex brand positioning is also related to its premiumness,  Sanex does not provide the emotional value to the customer. The positioning need to work upon and category may need to be chosen. As In deodorant brands multiple variants are possible, marketing tricks can be used to brand them separately in different markets as per needs
+
  
−
* As per the positioning map there are two major emotional spaces, where there is good scope of growth and can be used to create a stronger positioning for that segment
+
'''Boston Scientific Corporate Headquarters'''                                                        
−
1) '''Sporty Appeal''' – Adidas being only player working in the category, and as per the consumer behavior report, Sports deodorants acted as a trigger in the deodorant sales, Sanex can have a variant in this category to cater the segment
+
  
−
2) '''Masculine Emotional Space – '''Old Spice acts as an old premium brand in this category for last many years. Sanex (as it being a non premium brand) can launch a variant in this category as a mass brand, and can target those who aspire for masculine appe
+
One Boston Scientific Place
  
−
&nbsp;
+
Natick, MA 01760-1537
  
−
==References==
+
Main Number: 1-508-650-8000
−
* [http://www.euromonitor.com/ Euromonitor]
+
−
* [http://www.mintel.com/ Mintel]
+
−
* [[media:3027409.pdf|Top 100 Cosmetic Manufacturers]]
+
−
* [[media:2007_I.pdf|Global Deodorant Industry insights in 2007]]
+
−
* [[media:Getdocument.pdf|European Deodorant Market Insight]]
+
−
* [http://www.russiaretail.com/70111/Outlook-on-deodorant-market.shtml Outlook of Russian Deodorant Market]
+
−
* [[media:Cb_russia.pdf|Consumer Behave Insights from Russia]]
+
−
* [http://www.thesun.co.uk/sol/homepage/news/152296/Brits-win-pong-contest.html?print=yes Consumer Behavior Insights from UK]
+
−
* [http://www.bucharestherald.ro/dailyevents/41-dailyevents/21504-survey-two-toothpaste-tubes-four-bars-of-soap-and-one-deodorant-thats-how-much-romanians-use-in-a-year Consumer Behavior Insights from Romania]
+
−
* [http://www.guardian.co.uk/world/2011/mar/25/french-stereotypes-failure-wash Consumer Behavior Insights from France]
+
−
* [http://online.wsj.com/article/SB10001424052748703696704576223112705412404.html Consumer Insights derived from a study conducted by Unilever]
+
−
* [http://thefranknewsblog.blogspot.com/2010/07/news-from-body-shop.html Consumer Behavior Insights from a study conducted by Body Shop]
+
−
* [http://europa.eu/rapid/pressReleasesAction.do?reference=IP/11/684/ European Commission - Press release Mergers: Commission approves acquisition of Sanex by Colgate]
+

Latest revision as of 02:01, 9 September 2011

Boston Scientific

Company Overview

Key Facts

Boston Scientific (founded in 1979) is a worldwide developer, manufacturer and marketer of medical devices with approximately 25,000 employees and revenue of $7.8 billion in 2010. For more than 30 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The company’s products help physicians and other medical professionals improve their patients’ quality of life by providing alternatives to surgery.

Type Public Company
Company Size 10,001+ employees
Website http://www.bostonscientific.com
Industry Medical Devices
Founded 1979
Primary business divisions
  1. Cardiology, Rhythm and Vascular
  2. Endoscopy
  3. Urology and Women’s Health
  4. Neuromodulation
Key products

1) Taxus, Liberté, and Express coronary stents

2) Cognis cardiac resynchronization therapy defibrillator

3) Confient, Teligen, and Vitality implantable cardioverter defibrillators

4) Explorer and Inquiry diagnostic cardiology catheters

5) iLab ultrasound imaging system; Atlantis SR Pro ultrasound imaging catheter

6) Polyflex, Ultraflex and Wallflex esophageal, duodenal, and colonic stents

7) Sterling balloon dilation catheters

8) VersaPulse PowerSuite holmium urology laser systems

(Pharmalive)

Significant subsidiaries

1) Advanced Stent Technologies Inc.

2) Boston Scientific Neuromodulation Corp.

3) Cardiac Pacemakers Inc.

4) Catheter Innovations Inc.

5) Corvita Corp.

6) EndoVascular Technologies Inc.

7) Enteric Medical Technologies Inc.

8) Guidant Corp.

9) Intermedics Inc.

10) Interventional Technologies LLC

11) Precision Vascular Systems Inc

(Pharmalive)

Key Financials

Financials of Boston Scientific in 2010 (in $M)
Revenue (Fiscal Year) 7,806
Revenue Growth (1 yr) (-4.70%)
Gross Profit 5,207
EBITDA 1,859
Trading Statistics (in $M)
Market Capitalization 10,758.57
Shares Outstanding 1,528.21
Ratios
Current Ratio 1.75
P/E Ratio 18.9
Debt to Equity Ratio 43.31
Segment contribution
Segment Contribution to the revenue (in $M)
Segment Growth Sales (2010)
Cardiovascular (-5%) 811
Interventional Cardiology (-8%) 635
Peripheral Interventions 7% 176
Coronary stent system (-7.9%) 409
Cardiac Rhythm Management 4% 559
Defibrillators 6.9% 417
Pacemakers (-4%) 142
Electrophysiology (-3%) 37
Endoscopy (-3%) 287
Urology/Women’s health 10% 120
Neuromodulation 14% 77

Boston Scientific derives maximum contribution from Cardiovascular, which recorded a 5% year-over-year decline in sales to $811 million. While sales from Interventional Cardiology declined 8% to $635 million, Peripheral Interventions increased 7% to $176 million. Global sales of coronary stent system (within Interventional Cardiology) at $409 million declined 7.9% driven by lower sales of both drug-eluting stents (DES, 6.9% to $379 million) and bare-metal stents (18.9% to $30 million). It is encouraging to note that the company maintained its leadership position in the global DES market with 36% share and 46% in the US market.

The next biggest contributor to Boston Scientific’s top line, Cardiac Rhythm Management, recorded a 4% increase in sales to $559 million. A 6.9% rise in defibrillators sales to $417 million coupled with a 4% decline in sales of pacemakers to $142 million contributed to the overall increase.

Hence, the overall revenue of Boston Scientific declined by 4.7%. (Seekingalpha.com)

Revenue Distribution of Boston Scientific

By Product Category

Revenue - productwise - Boston scientific.jpg

The graph clearly shows the declining cardiovascular market, which constitutes the major part of Boston Scientific’s revenue. It gives a strong signal to the company to diversify its business into other business units and not be very dependent on one market.

By Geography

Revenue - geogwise - Boston scientific.jpg

*EMEA – Europe, Middle East and Africa

The graph clearly shows that U.S. contributes to more than 50% of the company’s revenues. It shows an opportunity for the company to expand in other markets. They have started selling their products in Japan, which has already started contributing majorly to the revenues.

Business Overview

Product Portfolio

Product Portfolio of Boston Scientific
Cardiovascular Group Cardiac Rhythm Management Endoscopy Urology and Women’s Health Neuromodulation
Drug-Eluting Stents Remote Patient Management Biliary Devices Stone Management Spinal Cord Stimulation
Coronary Balloons Pacemakers Cholangioscopy Benign Prostatic Hyperplasia
Coronary Atherectomy Implantable Cardioverter Defibrillators Biliary Stents Pelvic Floor Reconstruction
Embolic Protection Cardiac Resynchronization Gastrointestinal Stents Abnormal Uterine Bleeding
Inflation Devices Therapy Defibrillators Tissue Acquisition
Peripheral Balloons Cardiac Resynchronization Gastrointestinal Bleeding
Interventional Oncology Therapy Pacemakers Balloon Dilatation
Guide Wires Electrophysiology Pulmonary Devices
Diagnostic Catheters Ablation Catheters Airway Stents
Guide Catheters Intracardiac Echocardiography Bronchial Thermoplasty
Intravascular Ultrasound Diagnostic Catheters
Vascular Access/Chronic Total Occlusion
Peripheral Stents

Geographical Presence

The Corporate headquarters of Boston Scientific is in Natick, Massachusetts. The company is present in the following locations in Europe/Middle East/Africa, America and Asia Pacific/Japan.

Europe/Middle East/Africa America Asia Pacific/Japan
Austria Argentina New Zealand
Belgium Brazil China
Czech Republic Canada Hong Kong
Denmark Chile India
Finland Colombia Korea
France Costa Rica Tokyo
Germany Mexico Fukuoka
Greece Uruguay Hiroshima
Hungary Venezuela Kanagawa
Ireland West Indies Ishikawa
Israel Massachusetts Saitama
Italy California Miyazaki
Lebanon Florida Aichi
Netherlands Indiana Osaka
Norway Minnesota Hokkaido
Poland Utah Miyagi
Portugal Washington Kanagawa
Spain Malaysia
South Africa Philippines
Sweden Singapore
Switzerland Taiwan
Turkey Thailand
United Kingdom

Organization Structure

Organization Structure of Boston Scientific.jpg (Theofficialboard.com)

Key Executives

  • Chairman: Peter M. (Pete) Nicholas
  • EVP and COO: Samuel R. (Sam) Leno
  • EVP and CFO: Jeffrey D. (Jeff) Capello

Market Overview

Market Share

Market Share - Medical Devices (2010).jpg

Top 10 companies in the medical devices industry

Top 10 companies in the medical devices industry Sales in 2010 ($B)
Johnson & Johnson 23.60
Siemens Healthcare 17.40
GE Healthcare 16.00
Medtronic 15.82
Baxter International 12.60
Philips Healthcare 11.20
Abbott Laboratories 8.40
Boston Scientific 8.00
Covidien 7.81
Becton Dickinson 7.16

SWOT Analysis of Boston Scientific

SWOT - Boston Scientific.jpg

Transactional Activities

Mergers & Acquisitions done by Boston Scientific
<width="100%">|align = "right"| Acquired Company <width="100%">| Date <width="100%">| Value ($) M <width="100%">| Reason for Acquisition
Atritech Inc Jan-11 100 * It strengthens the BS’s product offerings in the fast-growing areas of structural heart therapy
* Also a trial fibrillation, which represent two of their Priority Growth Initiatives.
(Alacrastore.com)
ReVascular Therapeutics Inc Feb-11 N/A * These two novel technologies treat peripheral chronic total occlusions (CTOs).
* BSX made the acquisitions because the devices cover areas with promise of high growth potential. (Yahoo Finance)
Intelect Medical Inc Jan -11 78 * It supports BSX long-term strategy of enhancing the product portfolio and gaining market share in the Neuromodulation space
* It will help them to provide the most advanced deep brain stimulation technology solutions for neurologists, neurosurgeons and their patients.
* The GUIDE DBS system would be a major advance in deep brain stimulation therapy, especially when used in conjunction with BSX’s Vercise DBS System. (Massdevice.com, Medicaldesign.com)
Sadra Medical Inc Jan -11 193 * Will Help BSX leverage on its clinical expertise and existing sales channels in the fast-growing area of structural heart therapy.( Reuters)
Asthmatx Inc Oct-10 193.5 * Named as Top Ten Medical Innovations for 2007" by the Cleveland Clinic Foundation.
* The transaction is expected to provide meaningful revenue growth in the midterm (Asthmatx.com)
Labcoat Ltd . (Ireland) Sep- 10 N/A * The Technology represents a major advance for drug-eluting stents and would help BSX maintain their strong position in this market (Bostonscientific)
Remon Medical Technologies Inc Aug-07 . 73 * Provides BSX with innovative sensor and wireless communication technology that complements their Cardiac Rhythm Management product line.
* Also to maintain the leadership position (Salesandmarketingnetwork.com)
EndoTex Interventional Systems Inc . Jan-07 142 * leadership in treating carotid artery disease (Reuters)
Guidant Corp Apr-06 27000 * To be a global leader in cardiovascular devices (Cbsnews)
TriVascular Apr-05 110 * To increase its share in the overall market for abdominal aortic aneurysms (AAA)device (Fdanews)

Roadmap

Company’s focus on R&D

Employees split-2.jpg US Patents issued (Boston Scientific).jpg R&D investment - Boston.jpg

(Similar companies are based on the same industry and similar size for the year 2011)

  • The first chart shows the number of employees in the R&D department in Boston Scientific is 9% higher than the industry standards (in 2011). The other chart shows that over the span of 8 years (2002-2009), the investment by Boston Scientific in R&D has increased by 200%. Also, by the end of 2009, 7240 US patents have been granted to Boston Scientific and 10,009 patents are pending. It shows that Boston Scientific is clearly focused on investing in new technology through R&D.
  • In addition to the Company’s internal investments, Boston Scientific is committed to investing in external, or acquired, R&D through acquisitions and investments in new businesses.
  • Boston Scientific in future is committed to developing less-invasive products and procedures, and through the acquisition of new technologies, to better enable physicians to treat their patients.
  • The sales force of Boston Scientific is 3% lower than the industry standards. This shows that the company has an established customer base that are loyal to the company and Boston Scientific does not have to push is products in the market.

Key Insights

  • Boston Scientific continues to focus on strategic initiatives to drive growth and profitability. Till now USA has been the major geographical market for this company but Japan is emerging post 2008
  • Recent acquisitions made by the company along with promising new technologies are expected to boost the company's pipeline
  • Boston Scientifics' core businesses are witnessing significant pricing pressure and market decline. Due to which the revenues have gone down by 4.70% for the fiscal year 2010.Moreover, the economic uncertainty is impacting its procedure volume.
  • The dependence on Cardiovascular segment is very high and cannot be ignored. As its witnessing several challenges including pricing pressure, intense competition and slower market growth leading to a decline ranging between 3-8% annually
  • There are a few segments like urology/ women's health, neurovascular & Neuromodulation which have shown higher growth percentage that reaches up to 14% but the contribution of these segments is very low despite higher growth rate. Though this higher growth rate can be a signal of growth potential for future concentration of efforts
  • Company needs to realign their business portfolio to improve leverage and accelerate profitable revenue growth. The Company's diversification in Neuromodulation has been considered as a good decision by industry professionals
  • Co. Faces certain industry risks such as failure of approval from FDA, approved devices being pulled from market due to safety reasons along with eroding market share and expiring patents. The recent example of pull back is the iCross Coronary Imaging Catheters
  • It's been noted that their long standing approach to growth is by strategic acquisitions of , investments in or alliances with other businesses or companies but the co. may not always be successful in generating growth this way
  • BSX needs to control costs, grow foreign market revenue and has to continue to get timely regulatory approvals. Expansion of global sales and marketing focus is important along with Increasing its presence in markets such as China, India and Brazil and expanding the number of product registrations outside the U.S.
  • With respect to these declining figures new strategies need to be worked on, to either increase the contribution from this segment or diversify in to other segments

Contact

Boston Scientific Corporate Headquarters

One Boston Scientific Place

Natick, MA 01760-1537

Main Number: 1-508-650-8000

Retrieved from "https://www.dolcera.com/wiki/index.php?title=Deodorants_Market_Analysis:_Acquisition_of_Sanex_by_Colgate&oldid=9524"